News

CMS approves Harrow’s pass-through application for corticosteroid TRIESENCE
Harrow (HROW) announced that the Centers for Medicare & Medicaid Services CMS has approved Harrow’s transitional pass-through application ...
Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL
Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Harrow’s transitional pass-through ...
UroToday22d
A Phase II, Single Arm, Multicentre Trial of Triamcinolone With a GnRH Analog for Castrate-Resistant Prostate Cancer (TRICREST).
Corticosteroids are active in castration-resistant prostate cancer (CRPC) by suppression of adrenal androgen production. Triamcinolone is an intramuscular steroid injection which has putative ...